Streetbeat News

Stock Prices

MBRX

Moleculin Biotech (NASDAQ:MBRX) is scheduled to release its quarterly earnings report on March 22, 2024, with an expected EPS of $-0.20. Historical data shows mixed reactions to past earnings, with the stock price often dropping post-announcement. Shares have declined 56.44% over the last year, indicating a bearish outlook among long-term investors.

Portfolio Pulse from Benzinga Insights

March 21, 2024 | 2:00 pm

FN

Fabrinet (NYSE:FN) has been analyzed by 4 analysts, showing diverse perspectives with a shift towards a more bullish outlook in the last 30 days. The average 12-month price target for FN is now $215.0, marking an 11.69% increase from the previous target of $192.50. Analyst actions include ratings adjustments and price target changes, reflecting updated market conditions and company performance. Fabrinet's financial health indicators such as market capitalization, revenue growth, net margin, ROE, ROA, and debt management suggest a strong market position and financial health.

Portfolio Pulse from Benzinga Insights

March 21, 2024 | 2:00 pm

STRR

Star Equity Holdings (NASDAQ:STRR) is scheduled to release its quarterly earnings report on March 22, 2024, with an expected EPS of $-0.08. Analysts and investors will be looking for the company to beat this estimate and provide positive guidance for future growth. Historical data shows mixed reactions in stock price to past earnings performances, with minor fluctuations following the announcements. Shares have seen a 13.43% increase over the last 52 weeks, indicating a generally positive outlook from long-term shareholders.

Portfolio Pulse from Benzinga Insights

March 21, 2024 | 2:00 pm

XHR

Analysts have recently updated their evaluations and price targets for Xenia Hotels & Resorts (NYSE:XHR), reflecting a mix of opinions but generally indicating a positive outlook. The average 12-month price target has been raised to $16.12, marking a 13.12% increase from the previous target. This adjustment comes after a period of varied ratings, with the most recent consensus being indifferent. Despite the optimistic price targets, Xenia faces challenges such as a decline in revenue growth, below-average net margin, and ROE, indicating potential difficulties ahead.

Portfolio Pulse from Benzinga Insights

March 21, 2024 | 2:00 pm

HUMA

Humacyte (NASDAQ:HUMA) is scheduled to release its quarterly earnings report on Friday, 2024-03-22, with an estimated EPS of $-0.24. Analysts and investors are keen on whether the company will surpass this estimate and provide positive guidance for the next quarter. Historically, Humacyte's stock price has shown sensitivity to both earnings outcomes and forward guidance. The stock was trading at $3.51 as of March 20, reflecting a 24.4% increase over the last 52 weeks.

Portfolio Pulse from Benzinga Insights

March 21, 2024 | 2:00 pm

AGRX

Agile Therapeutics (NASDAQ:AGRX) is scheduled to release its quarterly earnings report on March 22, 2024, with analysts expecting an EPS of $-0.54. The company's past earnings performance shows a pattern of beating EPS estimates but experiencing subsequent share price drops. Shares are currently trading at $0.579, marking a 95.04% decline over the last year. Investors are particularly focused on the company's guidance for future growth.

Portfolio Pulse from Benzinga Insights

March 21, 2024 | 2:00 pm

NBIX

Neurocrine Biosciences' stock (NBIX) experiences an uptick as traders share news of it being selected by Investor Business Daily SwingTrader.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 2:00 pm

AAPL

GOOGL

MSFT

Apple Inc. is in discussions with both Alphabet Inc.'s Google and Microsoft Corp.-backed OpenAI to potentially integrate their large-language AI models into the iPhone's AI features, aiming to enhance Siri and other on-device capabilities. No decision has been made yet, and any formal announcement is not expected until the summer. The talks are part of Apple's broader strategy to advance its AI capabilities, with iOS 18 playing a significant role. Analysts see a potential partnership, especially with Google, as a win-win, potentially benefiting Google through substantial annual payments and distribution across Apple's vast device ecosystem.

Portfolio Pulse from Rounak Jain

March 21, 2024 | 1:56 pm

TBBK

Shares of The Bancorp Inc (NASDAQ:TBBK) moved lower following a report by Culper Research, titled 'The Bancorp Inc (NASDAQ:TBBK): Bridge To Nowhere'. The report likely raises concerns about the company's future prospects or current operations, leading to a negative impact on investor sentiment and the stock's performance.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 1:55 pm

DWAC

David Faber reported on CNBC that Trump Media will have immediate access to 87.5M shares, with Trump gaining an additional $30M in shares if the stock remains above $17.50 for 20 trading days. Trump's total of 127.5M shares could be valued at approximately $5.6B. Following this news, shares moved lower.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 1:53 pm